Hospital-acquired infections used to be a manageable problem. Then the antibiotics started failing. A 2024 study out of Turkey tested whether an old antiseptic — drinkable Lugol's iodine — has anything left to offer against the exact pathogens driving the crisis. The answer is interesting, and it's more modest than the headlines you'd want to write.

The Problem: Five Pathogens, One Shared Trait

The study targeted organisms that cause widespread nosocomial (hospital-acquired) infection — and every one of them was a multidrug-resistant clinical isolate:

• Acinetobacter baumannii
• Klebsiella pneumoniae (named in the abstract among the target group)
• Escherichia coli
• Pseudomonas aeruginosa
• Staphylococcus aureus
• Shigella sonnei

These aren't lab reference strains. They were isolated from patients at Iğdır State Hospital and confirmed resistant using the VITEK 2 system. The resistance profile in the paper's first table is brutal: A. baumannii was resistant to seven of the eight antibiotics tested. P. aeruginosa was resistant to five. These are the organisms that make infectious disease physicians lose sleep.

The authors' framing is worth quoting directly, because it's the whole rationale:

"Antiseptics do not target a specific area as antibiotics do. Since it targets many regions in microorganisms, it prevents the development of antimicrobial resistance."

The Mechanism: Why Iodine Is Structurally Different

Lugol's solution is roughly 85% water, 5% elemental iodine (I2I_2I2), and 10% potassium iodide (KIKIKI). The potassium iodide exists to solubilize the elemental iodine; the free I2I_2I2 is the active species.

Iodine kills by oxidation at multiple simultaneous targets:

• It attacks sulfhydryl (−SH-SH−SH) groups on microbial enzymes
• It disrupts protein synthesis
• It oxidizes nucleotides

A single-target antibiotic — say, a beta-lactam hitting penicillin-binding proteins — can be defeated by one mutation or one acquired enzyme. An agent that hits a dozen targets at once presents no such single point of failure. That's the theoretical reason iodine retains broad activity after nearly two centuries of use while whole antibiotic classes have been hollowed out by resistance.

The paper notes iodine's spectrum extends across multidrug-resistant bacteria, Pseudomonas aeruginosa, Mycobacterium tuberculosis, fungi, viruses, and protozoa. The historical record backs this: the authors cite Joseph Lister's 1867 Lancet paper on antiseptic surgery, and Akatsu and Noguchi's 1917 work on iodide compounds against drug-resistant spirochetes.

The Results: What the Numbers Actually Say

The study used two standard methods — broth microdilution for MIC values and disk diffusion for zone diameters — against a 1% Lugol's preparation. The experiment was run three times and averaged.

Minimum Inhibitory Concentrations:

For context on the dilution series: the plate ran from 5 μg/mL\mu g/mLμg/mL down to 0.078 μg/mL\mu g/mLμg/mL. Four of the five organisms were inhibited at 0.156 μg/mL\mu g/mLμg/mL — two steps below the highest concentration tested. E. coli needed 0.312 μg/mL\mu g/mLμg/mL.

That is genuinely low. Sub-microgram-per-milliliter inhibition of a seven-antibiotic-resistant A. baumannii isolate is a real finding, and it's the number the paper is built around.

On the disk diffusion side, the authors tested four concentrations (111, 10−110^{-1}10−1, 10−210^{-2}10−2, 10−310^{-3}10−3) and found the best result at the 10−110^{-1}10−1 dilution. DMSO served as the negative control.

The Wider Literature the Paper Draws On

The study's reference list is a useful map of what's already known — and every one of these is a real, citable source:

• Grønseth et al. (2023), International Wound Journal — Lugol's solution and gentian violet eradicated MRSA biofilm in skin wound infections; 5% Lugol's applied to mouse skin for five days significantly reduced MRSA and cleared the biofilm.
• Grønseth et al. (2017), International Journal of Pediatric Otorhinolaryngology — Lugol's solution eradicated Staphylococcus aureus biofilm in vitro.
• Hendley et al. (1978), Antimicrobial Agents and Chemotherapy — a 1% aqueous iodine solution was highly effective at eliminating infectious rhinovirus from fingertip rinses.
• Tam et al. (2006), Journal of Antimicrobial Chemotherapy — iodine formulations interfered with Streptococcus mutans biofilm formation on teeth.
• Tonoyan et al. (2018), Toxicology in Vitro — comparative cytotoxicity study of iodine-based biocides against E. coli.
• Du et al. (2023), Microorganisms — iodine reduced Candida viability in a dose-dependent manner.
• Ibrahim et al. (2021), Molecular Biology Reports — multidrug-resistant A. baumannii as an emerging hospital concern.

The pattern across these: iodine's documented wins cluster around biofilm, topical, and surface applications. That's not an accident, and it matters for how you read the new study.

What the Study Does Not Show

Here's the section most write-ups on this topic skip, and skipping it is how a good argument gets discredited.

This is an in vitro study. Bacteria in brain-heart infusion broth and on Mueller-Hinton agar are not bacteria in a human body. There is no immune system, no mucus layer, no tissue penetration problem, no thyroid, no gastric acid, no renal clearance. The paper says so itself:

"We think that it should be tested on cytotoxicity and live experimental animals."

The authors explicitly call for cytotoxicity testing and animal models as the next step. That's not a footnote — it's the honest boundary of what they demonstrated.

The concentration question is not the dosing question. An MIC of 0.156 μg/mL\mu g/mLμg/mL in a well tells you what inhibits growth in that well. It tells you nothing about what concentration is achievable at an infection site in a living person, or what that concentration does to human tissue along the way. In vitro potency and clinical efficacy are different measurements.

The paper's own conclusion is more cautious than its title suggests:

"There is insufficient data regarding Lugol's solution to prove that it will contribute to alternative treatment by preventing antibiotic resistance."

They also note that while there are anecdotal reports of individuals being cured, "no experimental results have been found in the laboratory environment" for nosocomial agents like A. baumannii and P. aeruginosa prior to this work. The study is a first step, and the authors describe it as one.

The cytotoxicity signal is real and worth naming. The paper cites work showing that Lugol's cytotoxic effect is characterized by increased oxidative stress and decreased superoxide dismutase and catalase activity. An agent potent enough to kill a seven-drug-resistant A. baumannii at sub-microgram concentrations is, by definition, chemically aggressive. That cuts both ways.

Why This Matters Anyway

The antibiotic pipeline is not keeping pace with resistance. The paper's framing — that multidrug-resistant bacteria are increasing while newly approved antibiotics decline — is not controversial; it's the consensus position in infectious disease.

Against that backdrop, a cheap, stable, broad-spectrum agent with a multi-target mechanism that resistance struggles to defeat is worth investigating seriously. Iodine has been in continuous use since Lister. It hasn't been rendered useless by resistance the way so many antibiotics have. That durability is the actual story here.

What this study adds is a clean, quantified demonstration that a 1% Lugol's preparation inhibits five clinically-derived MDR strains at concentrations between 0.156 and 0.312 μg/mL\mu g/mLμg/mL. That's a legitimate contribution to a genuinely thin literature — the authors note the scarcity of data on Lugol's against these specific organisms repeatedly.

What it does not add is evidence that drinking Lugol's treats resistant infections in people. That study hasn't been done.

The Bottom Line

• Established: Iodine's multi-target oxidative mechanism makes resistance development far harder than for single-target antibiotics.
• New here: A 1% Lugol's solution inhibited five multidrug-resistant clinical isolates at MICs of 0.156–0.312 μg/mL\mu g/mLμg/mL in vitro.
• Not established: Any clinical efficacy, any safe systemic dose, any in vivo result. The authors themselves call for animal and cytotoxicity studies next.
• The gap: The literature on Lugol's against MDR nosocomial pathogens is genuinely sparse, which is exactly why this paper exists.

The honest headline is that an old antiseptic just showed meaningful in vitro activity against some of the worst hospital pathogens we have. That's a real result, and it's more interesting than an overclaim. The follow-up studies the authors are asking for are the ones that will decide whether it means anything for patients.

This is informational only — not medical advice. Iodine is not inert; the thyroid concentrates it, and chronic excess can cause both hypo- and hyperthyroidism depending on the individual. Anyone considering ingestible iodine should consult a qualified professional first.